Your browser doesn't support javascript.
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months.
Santopaolo, Marianna; Gregorova, Michaela; Hamilton, Fergus; Arnold, David; Long, Anna; Lacey, Aurora; Oliver, Elizabeth; Halliday, Alice; Baum, Holly; Hamilton, Kristy; Milligan, Rachel; Pearce, Olivia; Knezevic, Lea; Morales Aza, Begonia; Milne, Alice; Milodowski, Emily; Jones, Eben; Lazarus, Rajeka; Goenka, Anu; Finn, Adam; Maskell, Nicholas; Davidson, Andrew D; Gillespie, Kathleen; Wooldridge, Linda; Rivino, Laura.
  • Santopaolo M; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Gregorova M; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Hamilton F; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Arnold D; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Long A; Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Lacey A; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Oliver E; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Halliday A; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Baum H; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Hamilton K; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Milligan R; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Pearce O; Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Knezevic L; Bristol Veterinary School, University of Bristol, Bristol, United Kingdom.
  • Morales Aza B; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Milne A; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Milodowski E; Bristol Veterinary School, University of Bristol, Bristol, United Kingdom.
  • Jones E; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Lazarus R; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Goenka A; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Finn A; Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom.
  • Maskell N; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Davidson AD; Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom.
  • Gillespie K; School of Population Health Sciences, University of Bristol, Bristol, United Kingdom.
  • Wooldridge L; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Rivino L; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Elife ; 122023 06 13.
Artículo en Inglés | MEDLINE | ID: covidwho-20242416
ABSTRACT
Coronavirus disease-19 (COVID-19) causes immune perturbations which may persist long term, and patients frequently report ongoing symptoms for months after recovery. We assessed immune activation at 3-12 months post hospital admission in 187 samples from 63 patients with mild, moderate, or severe disease and investigated whether it associates with long COVID. At 3 months, patients with severe disease displayed persistent activation of CD4+ and CD8+ T-cells, based on expression of HLA-DR, CD38, Ki67, and granzyme B, and elevated plasma levels of interleukin-4 (IL-4), IL-7, IL-17, and tumor necrosis factor-alpha (TNF-α) compared to mild and/or moderate patients. Plasma from severe patients at 3 months caused T-cells from healthy donors to upregulate IL-15Rα, suggesting that plasma factors in severe patients may increase T-cell responsiveness to IL-15-driven bystander activation. Patients with severe disease reported a higher number of long COVID symptoms which did not however correlate with cellular immune activation/pro-inflammatory cytokines after adjusting for age, sex, and disease severity. Our data suggests that long COVID and persistent immune activation may correlate independently with severe disease.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Estudio pronóstico Tópicos: Covid persistente Límite: Humanos Idioma: Inglés Año: 2023 Tipo del documento: Artículo País de afiliación: ELife.85009

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Estudio pronóstico Tópicos: Covid persistente Límite: Humanos Idioma: Inglés Año: 2023 Tipo del documento: Artículo País de afiliación: ELife.85009